Navigation Links
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
Date:5/14/2008

New President/CEO and Executive Chairman Set Sights on Expanding Therapeutic Horizons of Revolutionary Approaches to Adult Stem Cell Biology

BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May 14 /PRNewswire/ -- Paul A. Grayson and John Mendlein have joined Fate Therapeutics as president and CEO and executive chairman, respectively. Grayson and Mendlein join a team of internationally recognized stem cell scientists, clinicians and investors dedicated to creating best-in-class therapeutics based on a new and proprietary understanding of the role of adult stem cells in human physiology and disease. Both are seasoned executives with successful track records of translating revolutionary science discoveries into innovative drug opportunities and building world-class biotechnology teams and organizations.

Fate Therapeutics is a pioneer the emerging field of renewal therapies. Company scientists are redirecting the fate of the body's adult stem cells to enable Fate's therapies to intervene in human disease, aberrant physiology or damaged tissue with "renewed" cellular health. Fate's ground-breaking and proprietary therapeutic reprogramming engine is focused on understanding and guiding the fundamental biological mechanisms that determine the fate of cells to create new drugs that can advance and reverse the development of adult stem cells to restore the balance of cell fate between regeneration and decline. The company's renewal therapies have the potential to offer new hope to patients afflicted with some of the most difficult to treat conditions including degenerative diseases such as diabetes, Parkinson's and Alzheimer's Disease, ALS, heart failure, stroke and paralysis; developmental disorders including Down syndrome; and metastatic cancers. Fate's approach is designed to therapeutically use or redirect normal adult or somatic cells inside the human body and does not require embryonic stem cells from humans or any other animal.

"Fate continu
'/>"/>

SOURCE Fate Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
5. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
6. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
9. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Synageva BioPharma Corp. ("Synageva") ... developing therapeutic products for rare disorders announced today ... Chief Operating Officer.  Reporting directly to Sanj ... Robert will oversee the planned global commercial launch ... LAL Deficiency, and will have responsibility for the ...
(Date:9/21/2014)... to produce ultra-thin "diamond nanothreads" that promise extraordinary properties, ... strongest nanotubes and polymers. A paper describing this discovery ... a professor of chemistry at Penn State University, will ... the journal Nature Materials . , "From a ... the threads we formed have a structure that has ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 ... urological and interventional radiology products and services, has ... subsidiary with Clinicon Corporation for its ... HealthTronics’ portfolio of minimally invasive, mobile, surgical technology—offering ... , Under the agreement, HealthTronics will make available ...
(Date:9/19/2014)... disease risks, the biological characteristics people care most about ... heightthe textbook example of a complex traitattributes like risk ... genetic and environmental influences, making it challenging to find ... typically mate two individuals that differ in key waysfor ... study their descendents, looking for genes that tend to ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2
... IgG1 Using UNOsphere S and CHT , ... , Henry Lai, PhD, and Samuel G Franklin, PhD, ... USA , , ... a variety of sources have been purified , using ...
... Agencourt offers primer walking sequencing of PCR products, ... submit your template in either raw or , ... Select from either single stranded coverage for confirmation sequencing , ... clone validation , purposes. , ...
... , RNAClean is a ... isolates RNA or cDNA from in vitro transcription, cDNA or RNA ... As gene expression profiling , analysis and ... effective, automated purification reagent is required. Traditional purification , ...
Cached Biology Technology:Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 3Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 4Primer Walking 2RNA & cDNA Purification Using RNAClean 2RNA & cDNA Purification Using RNAClean 3RNA & cDNA Purification Using RNAClean 4RNA & cDNA Purification Using RNAClean 5
(Date:9/19/2014)... will study multifunctional and specialized spinal cord nerve ... Science Foundation grant in the amount of $680,000 ... in the Department of Biology, OU College of ... between the multifunctional and specialized spinal cord nerve ... what connections they make. Berkowitz will collaborate ...
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2
... has demonstrated how a technique using lasers could be ... campaign supports one of the main objectives of the ... Carbon and climate Observation of Planet Earth) is one ... just completed assessment study. The mission concept, along with ...
... International Society for Stem Cell Research (ISSCR), the world,s ... guidelines for the responsible development of safe and effective ... summarizes the Guidelines for the Clinical Translation of Stem ... December issue of Cell Stem Cell , the ...
... for pregnancy - other asthma drugs have not been as ... using the same asthma drugs they were using before they ... be regarded as safe. More trials of other essential medicines ... and Efficiency in Health Care (IQWiG), more data from trials ...
Cached Biology News:ESA tests laser to measure atmospheric carbon dioxide 2ESA tests laser to measure atmospheric carbon dioxide 3The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3Pregnant women with asthma can be more confident about some medicines 2
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
ANTI STENOTROPHOMONAS MALTOPHILIA...
... tube handling and reagent dispensing Holds: ... - 96 x 0.3ml U-bottom Omnistrips ... Non-Skirted Plate - Thermo-Fast® 96 Semi-Skirted Plate ... Multiple workstations can be securely stacked Can be stored ...
... well Magnetic-Ring Stand is designed for paramagnetic ... microplates. The stand has a plastic base ... plate footprint. The use of 96 extremely ... easy magnetic separation. With this magnetic stand, ...
Biology Products: